Blanket Purchase Agreement 36F79720D0151-36E79720A0016
Award Date
8/1/20
Last Date to Order
7/31/25
Federal Agency
National Acquisition Center
Awardee
Janssen Products, LP
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a component of the U.S. Department of Veterans Affairs (VA), to Janssen Biotech Inc. (doing business as Centocor Ortho Biotech Inc.). The $15,000,000 single-award BPA has a period of performance from September 2024 through September 2025 and is for the provision of the oncology drugs BALVERSA (erdafitinib) and CARVYKTI (ciltacabtagene autoleucel). Janssen Biotech is a major pharmaceutical manufacturer that...
Janssen Products LP, a subsidiary of Johnson & Johnson, holds a multiple award Federal Supply Schedule (FSS-61-IB) contract for pharmaceutical products awarded by the U.S. Department of Veterans Affairs (VA). The contract has a potential value of $881 million through July 2025. Under this IDV, Janssen provides the VA with critical medications such as Sirturo (bedaquiline), an antitubercular drug, and Balversa (erdafitinib), an oncology treatment. Task orders are primarily awarded by...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer, to provide critical medications for the treatment of rare diseases such as pulmonary arterial hypertension. The $118.5 million BPA covers the period from August 2024 to August 2025 and allows the VA, Federal Bureau of Prisons, and other federal agencies to procure specialized drug therapies like...
The U.S. Department of Veterans Affairs (VA) awarded a $3.7 million Blanket Purchase Agreement (BPA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a large pharmaceutical manufacturer. The BPA allows VA medical facilities to place firm fixed price call orders for the oncology medications BALVERSA (erdafitinib) and Belzutifan (WELIREG) through July 2024. This streamlined procurement vehicle supports the VA's Veterans Health Administration (VHA) in maintaining a steady...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to United Therapeutics Corporation, a self-certified small disadvantaged business and for-profit manufacturer of pharmaceutical goods. The BPA has a ceiling value of $207,127,385 and a performance period extending through April 2026. It allows the VA to procure specialized pharmaceutical products from United Therapeutics' portfolio, including Orenitram, Remodulin, Tyvaso,...
The Blanket Purchase Agreement (BPA) is a federal contract indefinite delivery vehicle (IDV) awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Genzyme Corporation, doing business as Sanofi Genzyme. The BPA has a ceiling value of $3,000,000 and a period of performance from June 6, 2024 to June 5, 2026. The purpose of the BPA is to provide the VA with a streamlined contracting method to procure specialty pharmaceutical products,...
This Blanket Purchase Agreement (BPA) contract was awarded by the National Acquisition Center, a civilian agency, to Otsuka America Pharmaceutical Inc., a large pharmaceutical manufacturer. The $83,342,090.00 BPA is for the supply of the drug Jynarque (tolvaptan) to the Department of Veterans Affairs (VA) healthcare system. Jynarque is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The BPA was awarded under the Pharmaceuticals and Drugs Federal Supply Schedule...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center of the U.S. Department of Veterans Affairs (VA) to Urogen Pharma Inc., a pharmaceutical company specializing in the drug JELMYTO. The single-award BPA, valued at up to $2.5 million, was made under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and is valid through February 2026. The purpose of this BPA is to provide the VA with a streamlined procurement vehicle to order JELMYTO, a drug used to...
This Blanket Purchase Agreement (BPA) contract was awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Jazz Pharmaceuticals, Inc. as the prime contractor. The BPA is valued at $161,183,457.45 and has an ultimate completion date of August 15, 2025. The purpose of this BPA is to provide the VA with access to Jazz Pharmaceuticals' specialty pharmaceuticals, including Xyrem and Xywav, through an efficient procurement vehicle. Four call...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to UCB, Inc., a global biopharmaceutical company, under the General Services Administration's Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. The single-award BPA, valued at $264,295.45, covers the procurement of the drug ZilbrysQ to treat patients within the VA healthcare system. Additionally, UCB, Inc. holds a larger BPA valued at $609,090,892.65 that...